470 related articles for article (PubMed ID: 33952608)
1. Development and Verification of a Linked
Patilea-Vrana GI; Unadkat JD
Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
[TBL] [Abstract][Full Text] [Related]
2. Characterizing and Quantifying Extrahepatic Metabolism of (-)-Δ
Kumar AR; Patilea-Vrana GI; Anoshchenko O; Unadkat JD
Drug Metab Dispos; 2022 Jun; 50(6):734-740. PubMed ID: 35370140
[TBL] [Abstract][Full Text] [Related]
3. Hepatic Enzymes Relevant to the Disposition of (-)-∆
Patilea-Vrana GI; Anoshchenko O; Unadkat JD
Drug Metab Dispos; 2019 Mar; 47(3):249-256. PubMed ID: 30567877
[TBL] [Abstract][Full Text] [Related]
4. Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers.
Wolowich WR; Greif R; Kleine-Brueggeney M; Bernhard W; Theiler L
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):691-711. PubMed ID: 31114948
[TBL] [Abstract][Full Text] [Related]
5. Quantifying Hepatic Enzyme Kinetics of (-)-∆
Patilea-Vrana GI; Unadkat JD
Drug Metab Dispos; 2019 Jul; 47(7):743-752. PubMed ID: 31048453
[TBL] [Abstract][Full Text] [Related]
6. A Δ
Methaneethorn J; Poomsaidorn C; Naosang K; Kaewworasut P; Lohitnavy M
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):495-511. PubMed ID: 32266676
[TBL] [Abstract][Full Text] [Related]
7. Development of a Physiologically-Based Pharmacokinetic Model of Δ
Methaneethorn J; Naosang K; Kaewworasut P; Poomsaidorn C; Lohitnavy M
Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):487-494. PubMed ID: 32253721
[TBL] [Abstract][Full Text] [Related]
8. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
[TBL] [Abstract][Full Text] [Related]
9. Relating Observed Psychoactive Effects to the Plasma Concentrations of Delta-9-Tetrahydrocannabinol and Its Active Metabolite: An Effect-Compartment Modeling Approach.
Awasthi R; An G; Donovan MD; Boles Ponto LL
J Pharm Sci; 2018 Feb; 107(2):745-755. PubMed ID: 28942005
[TBL] [Abstract][Full Text] [Related]
10. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Carboxylesterase 1-mediated In Vivo Drug Interaction between Methylphenidate and Cannabinoids using Static and Physiologically Based Pharmacokinetic Models.
Qian Y; Markowitz JS
Drug Metab Dispos; 2022 Jul; 50(7):968-979. PubMed ID: 35512806
[TBL] [Abstract][Full Text] [Related]
12. Investigation of phase II metabolism of 11-hydroxy-Δ-9-tetrahydrocannabinol and metabolite verification by chemical synthesis of 11-hydroxy-Δ-9-tetrahydrocannabinol-glucuronide.
Hassenberg C; Clausen F; Hoffmann G; Studer A; Schürenkamp J
Int J Legal Med; 2020 Nov; 134(6):2105-2119. PubMed ID: 32808050
[TBL] [Abstract][Full Text] [Related]
13. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.
Schwilke EW; Schwope DM; Karschner EL; Lowe RH; Darwin WD; Kelly DL; Goodwin RS; Gorelick DA; Huestis MA
Clin Chem; 2009 Dec; 55(12):2180-9. PubMed ID: 19833841
[TBL] [Abstract][Full Text] [Related]
14. The impact of pregnancy and associated hormones on the pharmacokinetics of Δ
Authement AK; Isoherranen N
Expert Opin Drug Metab Toxicol; 2024; 20(1-2):73-93. PubMed ID: 38258511
[TBL] [Abstract][Full Text] [Related]
15. A vapourized Δ(9)-tetrahydrocannabinol (Δ(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents.
Manwell LA; Charchoglyan A; Brewer D; Matthews BA; Heipel H; Mallet PE
J Pharmacol Toxicol Methods; 2014; 70(1):120-7. PubMed ID: 24973534
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic Framework to Predict Maternal-Placental-Fetal Pharmacokinetics of Nifedipine Employing Physiologically Based Pharmacokinetic Modeling Approach.
Werdan Romão MA; Pinto L; Cavalli RC; Duarte G; de Moraes NV; Abduljalil K; Moreira FL
J Clin Pharmacol; 2024 May; 64(5):568-577. PubMed ID: 38305718
[TBL] [Abstract][Full Text] [Related]
17. Predicting Maternal-Fetal Disposition of Fentanyl Following Intravenous and Epidural Administration Using Physiologically Based Pharmacokinetic Modeling.
Shum S; Shen DD; Isoherranen N
Drug Metab Dispos; 2021 Nov; 49(11):1003-1015. PubMed ID: 34407992
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Maternal and Fetoplacental Concentrations of Cefazolin, Cefuroxime, and Amoxicillin during Pregnancy Using Bottom-Up Physiologically Based Pharmacokinetic Models.
Abduljalil K; Ning J; Pansari A; Pan X; Jamei M
Drug Metab Dispos; 2022 Apr; 50(4):386-400. PubMed ID: 35046066
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
[TBL] [Abstract][Full Text] [Related]
20. Understanding the Mechanism and Extent of Transplacental Transfer of (-)-∆
Kumar AR; Sheikh ED; Monson JW; Ligon SE; Talley RL; Dornisch EM; Howitz KJ; Damicis JR; Ieronimakis N; Unadkat JD
Clin Pharmacol Ther; 2023 Aug; 114(2):446-458. PubMed ID: 37278090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
